Denator-led Research Project Aims to Develop New Biomarker Discovery Platform for Cancer Diagnostics
News Apr 26, 2012
Denator AB has announced a joint research project, together with Erasmus Medical Center and Amsterdam Medical Center, which will be sponsored by the EU Eurostars program.
Aimed at developing a unique new biomarker discovery platform for cancer diagnostics, the project was ranked 3rd out of almost 300 European project applications.
The project will focus on the development and verification of a prototype platform to monitor specific protein/peptide degradation patterns in biological fluids and tissue sections using Denator’s proprietary heat-stabilization technology combined with an array of synthetic peptides.
Since degradation patterns are specific for different tissue types and also for specific diseases, this novel approach could enable the discovery of completely new disease markers to enable early cancer diagnosis.
Other partners in the consortium are based in The Netherlands at the Department of Neurology, Erasmus Medical Center, headed by Dr Theo Luider, and the Department of Gastroenterology, Amsterdam Medical Center, headed by Professor Jacques Bergman.
Dr. Theo Luider explained: “To utilize specific degradation patterns correlating to specific cancer types could provide the research community with an important tool to help advance the understanding of the complexity of cancer and eventual early diagnosis. This project holds the potential of immensely facilitating the diagnostic process.”
Olof Sköd, CEO of Denator, says: “This collaboration project will allow us to continue developing exciting new application areas for our heat stabilization technology. We are confident that working within such a strong team of innovative scientists presents a great opportunity for developing breakthrough diagnostic solutions.”
The Eurostars Programme is the European funding and support programme specifically dedicated to stimulating international collaborative research and innovation projects of small and medium enterprises.
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.